Episode 17. Case Rates and Monoclonal Antibody Therapy
COVID-19 Case Rates by Race
Q1: We’ve been talking a lot about children’s health and safety now that the school year has started. Can you tell us about how COVID-19 cases are increasing among children?
- The case rate for Black children is three times the rate of white or Asian children.
- The case rate for Pacific Islander and American Indian/Alaska Native children is even higher.
- Over half reported symptomatic COVID-19.
- One percent (349) required hospitalization.
- Over a third were due to close contact with other household members who had COVID-19.
Q2: How does that compare to the case rates among individuals overallBlack adults?
- There have been over 290,000 cases of COVID-19.
- The case rate for Black adults and children is twice the case rate for white adults and children.
- The case rates for Pacific Islander and American Indian/Alaska Native adults and children are close to three times the case rate for white adults and children.
Q3: What is being done to address the disparities you talked about?
- Some of the community based organizations already involved in Oregon’s COVID-19 response received funding to support vaccination.
- OHA’s vaccine planning unit addresses vaccine equity including partnership with pre-existing Community Partner Outreach Program (CPOP)
- Supporting outreach to farmworkers as described in the Protecting our Farmworkers Resource Guide. OHA is also collaborating with federal partners who are coordinating regional interstate efforts to support migrant seasonal farmworkers with H-2A visas.
- FEMA Mobile Vaccine Unit
- Oregon vaccine advisory committee
- Public posting of vaccination data
- Vaccine web page
- Vaccine info and resources for communities
- Communications campaign
Monoclonal Antibody Therapy
Q4: Are there treatments that can reduce the risk of being hospitalized for COVID-19?
- This is an effective treatment for people ages 12 and older at high risk of developing severe COVID-19.
- This is also an effective form of prevention for high-risk individuals who have been exposed to cannot gain immunity from the COVID-19 vaccines.
- Can reduce the risk of hospitalization when used in those with mild to moderate disease by 70%.
- When used as post exposure prophylaxis can reduce the risk of symptomatic disease by 81%.
Q5: Are these communities accessing this treatment now?
- 64 were white.
- 3 were Black/African American (currently experiencing highest rates of hospitalization)
- 2 were American Indian/Alaskan Native
- 1 was Asian
- 20 were other/not specified.
Q6: How does it work?
- Intravenous infusion puts the antibodies into your vein.
- Subcutaneous injection puts the antibodies into the fatty layer of your skin.
Q7: Who qualifies for this treatment?
- Chronic lung disease
- Chronic kidney disease
- Cardiovascular disease
- Sickle cell disease
- Neurodevelopmental disease
- Dependence on medical-related technologies, such as tracheostomy
Q8: How can we make sure everyone, including the Black community, is aware of this treatment?
- Pharmacists can now complete education and training to provide a specific monoclonal antibody product at the pharmacy or any other location that is appropriate.
- More traditional hHealth care providers can provide this treatment in the office setting.
Q9: Would it also help to share this information with our providers?